New naltrexone shot takes on vivitrol in early trial
NCT ID NCT05620940
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This early-stage trial tests a new long-acting naltrexone injection (IVL3004) against the approved drug Vivitrol in 40 healthy men. The goal is to compare how the drug moves through the body and check for safety. It does not yet test if it helps treat opioid or alcohol dependence.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
naltrexone long-acting injection
What this could lead to
If successful, this could lead to a new long-acting naltrexone option for treating opioid or alcohol dependence, potentially offering similar benefits to Vivitrol.
What could go wrong
This is a very early Phase 1 study in only 40 healthy men, not patients. It only checks drug levels and safety, not whether it actually works for addiction. Many early-stage drugs fail to show benefit later.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nucleus Network
RECRUITINGHerston, Queensland, 4006, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••